Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Belgium, Dél-Korea, Finnország, Kanada, Panama, Spanyolország és Tajvan10 helyszín, 7 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
68 fő vett részt
Kezdés
2019. dec. 9.
Befejezés
2024. jún. 27.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • HZ/su vaccine (GSK1437173A)
A regiszteradat frissítve
2025. július 18.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Inclusion criteria for enrolment; Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and subjects' Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol; Written informed consent obtained from the subject/LAR(s) of the subject prior to performance of any study-specific procedure; Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course
  • Inclusion criteria for revaccination; Subjects receiving maintenance CIS therapy for the prevention of allograft rejection for a minimum of one month prior to the first revaccination; Subjects without an episode of allograft rejection within 90 days prior to the first revaccination visit; Female subjects of non-childbearing potential may be revaccinated. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause; Female subjects of childbearing potential may be revaccinated, if the subject:
  • has practiced adequate contraception for 30 days prior to revaccination, and
  • has a negative pregnancy test on the day of revaccination, and
  • has agreed to continue adequate contraception up to 2 months after completion of the revaccination series

Ki nem vehet részt

  • Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study; Prior/Concurrent clinical study experience
  • Concurrently participating in another interventional vaccine or immunosuppressive clinical study, in which the subject is exposed to an investigational or a non-investigational vaccine/product (drug) at any time during the ZOSTER-073 study
  • Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study or make vaccination unsafe; Prior/Concomitant therapy
  • Administration or planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first revaccination dose of study vaccine and ending at Visit 5 (Month 26)
  • Use of anti-CD20 or other B-cell monoclonal antibody agents as maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months of first revaccination dose of study vaccine
  • Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of maintenance immunosuppressive therapies
  • Planned administration/administration of a live vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration
  • Planned administration/administration of a non-replicating or subunit vaccine, not foreseen by the study protocol, in the period starting 8 days before and ending 30 days after each dose of study vaccine; Other exclusion criteria for revaccination
  • Significant underlying illness that, in the opinion of the investigator, is expected to prevent completion of the study
  • History of confirmed HZ within one year before revaccination visit (Visit 3)
  • Any additional confirmed or suspected immunosuppressive or immunodeficient condition
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe
  • Vaccination against HZ since completion of study ZOSTER-041
  • More than one organ transplanted
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions up to 2 months post-revaccination Dose 2

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

7 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study also assessed immune responses as well as safety after revaccination with 2 additional doses of the HZ/su administered at 6 to 8 years after the 2-dose primary vaccination course.

A vizsgálat csoportja

  • HZ/su GroupA vizsgált kezelés

    Participants with renal transplant who completed the 2-dose Herpes Zoster (HZ/su) vaccination course in the primary ZOSTER-041 (NCT02058589) study were enrolled in the current ZOSTER-073 (NCT04176939) study. 47 of these participants further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of the current ZOSTER-073 (NCT04176939) study, first dose at Month 24 and second dose at Month 25.

    Kezelés: HZ/su vaccine (GSK1437173A)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
Publikációk
A regiszteradat frissítve
2025. július 18.